Biopharm company Alcobra (ADHD +4%) gets a lift from Aegis Capital this morning, who initiates...

|About: Alcobra Ltd. (ADHD)|By:, SA News Editor

Biopharm company Alcobra (ADHD +4%) gets a lift from Aegis Capital this morning, who initiates coverage with a Buy rating and a price target of $30 per share. The stock has been something of a disappointment since its IPO debut in May. It priced at $8 and immediately broke below on its first day of trading, and still remains 11% underwater.